Navigation Links
NanoPass Technologies Ltd. and Elcam Medical Enter Into a Strategic Partnership
Date:9/14/2010

NanoPass Technologies Ltd. and Elcam Medical Enter Into a... -- REHOVOT and KIBBUTZ BAR'AM, Israel, September 14, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Nanotechnology, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Contracts, Joint Ventures, Clinical Trials & Medical Discoveries Click to view news release full screen  

NanoPass Technologies Ltd. and Elcam Medical Enter Into a Strategic Partnership

 

REHOVOT and KIBBUTZ BAR'AM, Israel, September 14, 2010 /PRNewswire/ -- NanoPass Technologies Ltd. ("NanoPass"), a privately held company that develops novel microneedle solutions for painless delivery of drugs and vaccines, announced today that it has recently secured a strategic investment and manufacturing agreement with a leading medical device manufacturer, Elcam Medical ("Elcam"). Existing investors including Ofer Hi Tech and D Partners, also participated in the round.

As part of the investment, Mr. Ehud Raivitz, Elcam's CEO, and Mr. Ilan Neugarten of D Partners, will join NanoPass's Board of Directors. Ehud Raivitz remarked, "We are happy to enter into this partnership with NanoPass. I have been impressed by their innovative technology, positive clinical data and achievements. I look forward to leveraging Elcam's capabilities in production and engineering for the mutual benefit of both companies. The collaboration with NanoPass will enable Elcam to provide its customers with access to the most advanced intradermal delivery technology that can address their needs in various applications."

Dr. Yotam Levin, Chief Executive Officer of NanoPass, commented, "We are excited to enter into this strategic partnership with Elcam, a long time supplier of disposable medical products for the medical and pharma industries. We see a significant synergy between our companies. Along with the regulatory approvals we have recently obtained from the FDA and other regulatory bodies, securing a reliable and highly experienced manufacturer is a key component towards full commercialization of our products. The investment will allow NanoPass to develop additional pharmaceutical clients and prepare for market launch."

About NanoPass Technologies Ltd.

NanoPass Technologies was founded by Dr. Shuki Yeshurun under the auspices of the Naiot Technological Incubator. The company is backed by prominent Israeli and US investors including Ofer Hi Tech, D Partners, WFD Ventures, and more recently, Elcam Medical.

About NanoPass's MicronJet Device

MicronJet is a microneedle-based device for ID delivery of vaccines and drugs. The device allows for consistent, reliable, and simple delivery of the drugs directly into the skin. MicronJet has proven efficacy and safety in multiple applications including seasonal flu vaccines, insulin and lidocaine. MicronJet is approved for marketing in various leading territories.

NanoPass has recently concluded the world's first intradermal h1n1 pandemic flu vaccine study, demonstrating equivalent immunogenicity to intramuscular delivery using 20% of the dose. In other clinical trials conducted by NanoPass and third parties, it has been shown that injecting a seasonal influenza vaccine directly into the skin allows for the reduction of the dose required for the same immune response ("dose sparing"). Further, using an equivalent dose may actually increase a vaccine's immunogenicity.

About Elcam Medical

Elcam Medical (Bar-Am, Israel) is a leading worldwide OEM supplier, servicing the medical industry, specializing in the areas of Fluid Management, Vital Signs Monitoring and Drug Delivery.

Contact: Yotam Levin +972-8-9462905 +972-523-392727 yotam@nanopass.com
'/>"/>

SOURCE NanoPass Technologies LTD.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Energy technologies not enough to sufficiently reduce carbon emissions, NYUs Hoffert concludes
2. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
3. Reportlinker Adds Proteomics - Technologies, Markets and Companies
4. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
5. Statement From Sicel Technologies, Inc.
6. Medisafe 1 Technologies Announces 1-5 Stock Dividend
7. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
8. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
9. Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome
10. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
11. Looking to leap forward on laser and photodetector technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):